St. Jude Medical (NYSE:STJ) snatched a contract from group purchasing organization Novation after its Twin Cities competitor Medtronic (NYSE:MDT) walked away from a similar deal with the GPO in February.
Novation said the 30-month deal, which went into effect April 1, will see St. Jude supply it with cardiac rhythm management products — which were also part of the deal Medtronic spiked, which also included some orthopedic products. It includes provisions for “locally-negotiated pricing and market share growth rebates,” according to a press release, and is the first time the two companies have worked together.
Medtronic made headlines — pleased Wall Street — when it canceled several contracts for its cardiovascular and orthopedic products with Novation worth an estimated $2 billion a year. A few weeks later the Fridley, Minn.-based medical device giant spiked a deal with Premier Inc. for some of its spine products.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
After the Premier deal ended, Medtronic spokesman Chris Garland told MassDevice in an email that the decision to end both deals were made because the company felt it would do better negotiating contracts directly with hospitals.
“Our only comment is that we are confirming that our spinal business terminated a national contract with Premier,” Garland wrote. “We did this for the same reasons we terminated five Novation contracts earlier.”
Last month, Medtronic CFO Gary Ellis told analysts that spiking the deals wasn’t a strut in a larger strategic plan.
“There’s a lot of speculation around here that a strategic change is going on,” Ellis told analysts at the Barclay’s Capital Investors Conference in Miami. “That is not the case.”
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
GPOs play a significant role in the delivery of healthcare, Ellis noted, and they’re beneficial in streamlining the process of selling into hospital systems.
“We intend to maintain our relationships with GPOs that are providing a benefit,” he said.
Yesterday, Garland told us Medtronic that the company’s move to combine its cardiac and vascular groups’ sales forces into a single cross-divisional organization is part of its move to deal directly with hospital purchasing administrators.
Related articles
- Medtronic cancels contract with another purchasing organization (medcitynews.com)
- Hospitals under ‘attack’ from Medtronic strategy, trade group claims (medcitynews.com)
- Medtronic’s canceled supply contracts yield savings, rising shares (medcitynews.com)
- Medtronic to combine cardiac and vascular sales forces (medcitynews.com)
The Massachusetts Medical Devices Journal is the online journal of the medical devices industry in the Commonwealth and New England, providing day-to-day coverage of the devices that save lives, the people behind them, and the burgeoning trends and developments within the industry.
